Integration of gene-specific diagnostic criteria into LVEF-based classification improved identification of composite arrhythmia and heart failure events, with advanced disease (LVEF <40%) showing an HR of 10.3.
Observational (n=605)
Yes
Do genotype-specific diagnostic and disease staging criteria improve the identification of risk for heart failure and sustained ventricular arrhythmias in patients with Desmoplakin (DSP) cardiomyopathy?
Genotype-specific diagnostic and staging criteria for Desmoplakin (DSP) cardiomyopathy, incorporating PVCs, NSVT, LGE, and LVEF, accurately identify affected patients and stratify their risk for major arrhythmic and heart failure events.
Effect estimate: HR 10.3
p-value: p=<0.001
Abstract Background Desmoplakin (DSP) cardiomyopathy, caused by variants in the gene DSP , is a unique subtype of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathies. Specific diagnostic and disease staging criteria have yet to be developed for DSP cardiomyopathy. Objective Utilizing a large cohort of DSP cardiomyopathy patients and their genotype-positive family members, this study aims to develop diagnostic and disease staging criteria for DSP cardiomyopathy. Methods Patients from the DSP -ERADOS Network with complete rhythm monitoring, electrocardiogram and cardiac magnetic resonance imaging were enrolled. Diagnostic criteria were assessed in initially-presenting patients (probands) and their genotype-positive family members. Early disease criteria (with preserved left ventricular ejection fraction, LVEF) were integrated into standard LVEF-based classifications. Diagnostic and staging criteria were assessed by time-event analyses (major ventricular arrhythmia and heart failure events). Results A total of 605 patients with complete diagnostic testing were included (mean age 40 yr, 60% female, 40% probands). The most prevalent disease features in probands were premature ventricular contractions (PVCs) >500/24hr (66%), nonsustained ventricular tachycardia (NSVT, 29%), LV late gadolinium enhancement (LGE, 53%), and reduced LVEF (44%). The presence of any one of these features was 97% sensitive for diagnosis (along with a DSP pathogenic variant) and were therefore considered as diagnostic criteria. Using these criteria, 77% of genotype-positive family members were considered clinically affected. Isolated right ventricular (RV) involvement occurred in only 0.7%. The absence of diagnostic criteria identified a low-risk group (composite event rate 0.8%/year, p50%, HR 2.7, p=0.04; intermediate: LVEF 41-49%, HR 3.7, p=0.009; advanced: LVEF <40% HR 10.3, p<0.001). LGE was mostly subepicardial (87%). Circumferential (ring-like) LGE was more frequent in intermediate or advanced vs early disease (66% vs 48%, p<0.001). Conclusion This study identifies genotype-specific diagnostic and disease staging criteria for DSP cardiomyopathy that improve identification of risk for both heart failure and sustained ventricular arrhythmias. This work highlights how gene-specific criteria may be used to refine diagnosis and staging for cardiomyopathy subtypes – a critical step as gene-targeted treatments move toward clinical trials.
Smith et al. (Mon,) conducted a observational in Desmoplakin (DSP) cardiomyopathy (n=605). Gene-specific diagnostic and disease staging criteria vs. Absence of diagnostic criteria was evaluated on Composite of major ventricular arrhythmia or major heart failure events (HR 10.3, p=<0.001). Integration of gene-specific diagnostic criteria into LVEF-based classification improved identification of composite arrhythmia and heart failure events, with advanced disease (LVEF <40%) showing an HR of 10.3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: